Abstract
Six patients with advanced arteriosclerosis obliterans in the lower extremities were subjected to an exercise test on a tread mill with and without dipyridamole treatment. Prostacyclin (PGI 2) release was measured by the concentration of its stable metabolite, 6-keto prostaglandin F 1α in plasma. All the patients suffered from ischemic pain during both tests, but no changes were seen in plasma 6-keto-PGF 1α. Dipyridamole did not affect the physical performance. Our results suggest that atherosclerotic vessels do not increase PGI 2 production in response to ischemia and that a single dose of dipyridamole does not change PGI 2 production.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
